Belimumab
Benlysta (belimumab) is an antibody pharmaceutical. Belimumab was first approved as Benlysta on 2011-03-09. It is used to treat systemic lupus erythematosus in the USA. It has been approved in Europe to treat systemic lupus erythematosus. The pharmaceutical is active against tumor necrosis factor ligand superfamily member 13B.
| Trade Name | Benlysta |
|---|---|
| Common Name | Belimumab |
| Indication | systemic lupus erythematosus |
| Drug Class | Monoclonal antibodies |
